Company profile for Enara Bio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Enara Bio is exploring the hidden depths of cancer biology to discover and characterize novel immunotherapy targets, such as Dark Antigens derived from the genomic dark matter or cancer-specific antigens presented by MR1. To achieve our mission, we have built a differentiated technology platform integrating bioinformatics, immunopeptidomics, metabolomics and immunology that enables us to interrogate both sides of the T-cell/c...
Enara Bio is exploring the hidden depths of cancer biology to discover and characterize novel immunotherapy targets, such as Dark Antigens derived from the genomic dark matter or cancer-specific antigens presented by MR1. To achieve our mission, we have built a differentiated technology platform integrating bioinformatics, immunopeptidomics, metabolomics and immunology that enables us to interrogate both sides of the T-cell/cancer cell interface. Our growing team has the depth of expertise and breadth of experience to advance this exciting area of immuno-oncology for the benefit of broad groups of cancer patients and their families.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
The Magdalen Centre Oxford Science Park 1 Robert Robinson Avenue Oxford, OX4 4...
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/04/3180455/0/en/Enara-Bio-s-DARKFOX-Discovery-Propels-ENA101-the-First-Ever-Bispecific-T-Cell-Engager-Targeting-a-Cancer-Specific-Dark-Antigen-into-IND-Enabling-Studies.html

GLOBENEWSWIRE
04 Nov 2025

https://www.pharmiweb.com/press-release/2025-10-06/enara-bio-to-reveal-darkfox-a-novel-cancer-specific-dark-antigen-with-broad-ranging-therapeutic-potential-in-oral-presentation-at-sitc-2025

PHARMAWEB
06 Oct 2025

https://www.globenewswire.com/news-release/2025/10/03/3160977/0/en/Enara-Bio-to-Reveal-DARKFOX-a-Novel-Cancer-Specific-Dark-Antigen-with-Broad-Ranging-Therapeutic-Potential-in-Oral-Presentation-at-SITC-2025.html

GLOBENEWSWIRE
03 Oct 2025

https://www.globenewswire.com/news-release/2025/05/01/3072084/0/en/Enara-Bio-Strengthens-Senior-Leadership-with-Key-Executive-and-Board-Appointments-Alongside-Acceleration-of-Multiple-T-Cell-Engager-Programs.html

GLOBENEWSWIRE
01 May 2025

https://www.globenewswire.com/news-release/2024/10/03/2957454/0/en/Enara-Bio-raises-32-5-million-Series-B-financing-to-advance-first-in-class-pipeline-of-TCR-based-immunotherapies-targeting-novel-Dark-Antigens.html

GLOBENEWSWIRE
03 Oct 2024

https://www.globenewswire.com//news-release/2024/01/04/2803914/0/en/Boehringer-Ingelheim-licenses-multiple-Dark-Antigens-from-Enara-Bio-to-develop-off-the-shelf-immunotherapies-for-non-small-cell-lung-cancer-NSCLC.html

GLOBENEWSWIRE
04 Jan 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty